Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 March 2022Website:
http://www.conduitpharma.comNext earnings report:
30 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 12 min agoDividend
Analysts recommendations
Institutional Ownership
CDT Latest News
Initial joint project in Fuzhou expected to generate an increase in revenue by more than 50% over next three years Initial joint project in Fuzhou expected to generate an increase in revenue by more than 50% over next three years
Three Phase Project Will Process 400,000 Tons/Day and Has Initial Contract Value of 1.16B RMB Three Phase Project Will Process 400,000 Tons/Day and Has Initial Contract Value of 1.16B RMB
SHENZHEN, China, May 20, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) (“CDT”), a leading provider of waste treatment systems and services throughout China, today announces that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2024. The annual report on Form 20-F, which contains CDT's audited consolidated financial statements, can be accessed through the SEC's website at www.sec.gov or CDT's website at https://www.cdthb.cn.
The U.S. House of Representatives passed a bill on March 13 that stated a requirement for ByteDance, a reputable Chinese tech company, to ban TikTok in the United States. The legislation, now known as the Protecting Americans from Foreign Adversary Controlled Application Act , was forwarded by the U.S. government Reps.
Conduit Pharmaceuticals (NASDAQ: CDT ) stock is rocketing higher on Monday despite a lack of news from the biopharmaceutical company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why CDT stock is rising today.
Conduit just began trading on the Nasdaq on Sept. 25. The company focuses on advancing other pharmaceutical companies' deprioritized assets.
What type of business is Conduit Pharmaceuticals?
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
What sector is Conduit Pharmaceuticals in?
Conduit Pharmaceuticals is in the Healthcare sector
What industry is Conduit Pharmaceuticals in?
Conduit Pharmaceuticals is in the Biotechnology industry
What country is Conduit Pharmaceuticals from?
Conduit Pharmaceuticals is headquartered in United States
When did Conduit Pharmaceuticals go public?
Conduit Pharmaceuticals initial public offering (IPO) was on 28 March 2022
What is Conduit Pharmaceuticals website?
https://www.conduitpharma.com
Is Conduit Pharmaceuticals in the S&P 500?
No, Conduit Pharmaceuticals is not included in the S&P 500 index
Is Conduit Pharmaceuticals in the NASDAQ 100?
No, Conduit Pharmaceuticals is not included in the NASDAQ 100 index
Is Conduit Pharmaceuticals in the Dow Jones?
No, Conduit Pharmaceuticals is not included in the Dow Jones index
When does Conduit Pharmaceuticals report earnings?
The next expected earnings date for Conduit Pharmaceuticals is 30 August 2024